Tourmaline Bio Profit Margin

Tourmaline Bio posts a profit margin of -2211.85% as of June 2025. That is below the Healthcare sector average of 15.52%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a profit margin near 15.52% is typical. Tourmaline Bio's -2211.85% is lower that level. That is roughly 1425242.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Tourmaline Bio's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -2211.85% as of June 2025; use YoY and peer views to separate noise from signal.

Context for TRML's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.52%), and (3) consistency with growth and profitability. This page covers the first two; Tourmaline Bio's other metric pages and overview cover the third.

Judging Tourmaline Bio against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in profit margin easier to interpret. Start with -2211.85% here, then scan peer and history charts to see if the gap is persistent.